Empower the Patient – Increase Survival.
Empower their Community and Workplaces – Exponentially Increase Survival

“We, work to ensure that today’s research and knowledge are fully utilised and integrated into today’s patient toolkit. By simplifying both the science and the knowledge into formats that patients and caregivers can understand and apply, we help achieve this” ~ Steve Holmes 

MTAP Loss and the AMG193 Trial

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

Visit Clinical Trial

Cholangiocarcinoma Foundation Australia

Storified Version

Imagine a big school where every student (cell) has a special recycling bin at their desk (MTAP enzyme) that helps them turn used paper (a substance called MTA) into new books (important cell parts). This recycling process is crucial because, without it, students can’t get the materials they need to learn and grow.

One day, a few classrooms (cells) lose their recycling bins. These classrooms now have a big problem: they can’t recycle paper anymore, and they have to find new ways to get the materials they need. This makes life much harder for these students.

To make up for the loss of recycling bins, these classrooms start relying heavily on an internal helper called PRMT5. PRMT5 helps them manage their supplies by repurposing whatever materials they can find, even though it’s not as efficient as having the recycling bins.

Scientists noticed this problem and decided to help. They created a special robot named AMG193. This robot is designed to target PRMT5 directly. By disabling PRMT5, the robot makes it impossible for the struggling classrooms to keep functioning, effectively shutting them down.

The Clinical Trial

In the real world, this story is about a clinical trial testing the drug AMG193. This trial is aimed at patients with cancers that have lost the MTAP enzyme. By targeting PRMT5 with AMG193, scientists hope to specifically attack these vulnerable cancer cells and stop them from growing.

In summary, the trial is like sending a robot into the school to help take down the problem classrooms that lost their recycling bins and are now overly reliant on PRMT5, ensuring that the rest of the school can keep running smoothly. This approach could potentially lead to more effective treatments.

For more information about the AMG193 clinical trial, please visit this link

Navigator Journal and Digital Toolkits

Do you have your free Patient Navigator?

Become Part Of The Solution